article thumbnail

Certain menopausal hormone therapy could raise ovarian cancer risk, study finds

Bio Pharma Dive

The findings, from two trials involving tens of thousands of women, could influence guidelines around the use of hormonal treatment for menopausal symptoms.

Hormones 280
article thumbnail

Adakitug by Bristol-Myers Squibb for Hormone-Sensitive Prostate Cancer: Likelihood of Approval

Pharmaceutical Technology

Adakitug is under clinical development by Bristol-Myers Squibb and currently in Phase II for Hormone-Sensitive Prostate Cancer.

Hormones 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Crinetics Pharmaceuticals gets grant for patent granted for somatostatin modulators for treating hormone-related conditions

Pharmaceutical Technology

Discover how Crinetics Pharmaceuticals Inc's patent for compounds modulating somatostatin activity can suppress hormone secretion in mammals. Explore the detailed framework for hormone modulation and SSTR2 activity regulation.

Hormones 130
article thumbnail

The end of condoms? Will men embrace the hormone-free birth control pill?

Outsourcing Pharma

In an exclusive interview, Akash Bakshi, CEO of YourChoice Therapeutics, delves into the inspiration and journey behind developing a hormone-free birth control pill for men.

Hormones 104
article thumbnail

Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer by Cellbion for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Pharmaceutical Technology

Small Molecule to Target PSMA for Metastatic Hormone Refractory Prostate Cancer is under clinical development by Cellbion and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Hormones 130
article thumbnail

Abiraterone acetate by Tavanta Therapeutics for Hormone-Sensitive Prostate Cancer: Likelihood of Approval

Pharmaceutical Technology

Abiraterone acetate is under clinical development by Tavanta Therapeutics and currently in Phase III for Hormone-Sensitive Prostate Cancer.

Hormones 130
article thumbnail

Another delay for Ascendis' hormone therapy as FDA extends review by 3 months

Fierce Pharma

It’s been a long wait for Ascendis Pharma to score FDA approval for its hormone replacement therapy TransCon PTH (palopegteriparatide). It’s been a long wait for Ascendis Pharma to score FDA approval for its hormone replacement therapy TransCon PTH (palopegteriparatide).

Hormones 111